HENLIUS (02696.HK) received a shareholding increase of 0.2531 million shares listed in Hong Kong from Lin Lijun, worth approximately 6.0515 million Hong Kong dollars.

On January 2, it was reported that according to the documents disclosed by the Hong Kong Stock Exchange on January 2, Lin Lijun increased his Shareholding in $HENLIUS(02696.HK)$ by 253,100 H shares at an average price of HK$23.9094 per share on December 30, 2024, worth approximately HK$6.0515 million. After the increase, Lin Lijun's latest shareholding is 11.6694 million shares, with the good warehouse ratio rising from 6.98% to 7.14%. Image source: Stock disclosure from the Exchange. What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more) must disclose their holdings in listed companies.

Futu NewsJan 2 17:10

Express News | A total of 579 Hong Kong stocks were short-sold today, with a total short-selling amount of 25.906 billion Hong Kong dollars.

BreakingsJan 2 17:03

Shanghai Henlius Extends Promotional Partnership With Jiangsu Fosun

TipRanksDec 31, 2024 18:12

Seize the innovative leading value and explore the investment opportunities in Hong Kong stocks in the pharmaceutical sector after the deep pullback.

Since the beginning of this year, in the pharmaceuticals Sector, the Hong Kong stock market has demonstrated more cost-effective investment value compared to the A-shares.

Zhitong FinanceDec 29, 2024 16:33

HENLIUS (02696.HK) has completed the administration of the first patient in the Phase 3 clinical study of Lusutrombopag tablets.

HENLIUS (02696.HK) announced that the first patient in China has been treated in an international multicenter phase III clinical trial comparing HLX78 (lasofoxifene tablets) combined with abemaciclib versus fulvestrant combined with abemaciclib for the treatment of pre/postmenopausal women and men with locally advanced or metastatic breast cancer who have previously received aromatase inhibitors (AIs) combined with palbociclib or ribociclib, estrogen receptor positive, human epidermal growth factor receptor 2 negative, and carrying estrogen receptor 1 mutations.

AASTOCKSDec 27, 2024 00:40

Shanghai Henlius Begins Key Breast Cancer Drug Trial

TipRanksDec 24, 2024 17:37